Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (69)
  • Open Access

    RETRACTION

    Retraction: KIF18A is a potential prognostic factor and promotes tumor progression in oral tongue squamous cell carcinoma

    BIOCELL Editorial Office

    BIOCELL, Vol.48, No.6, pp. 1009-1009, 2024, DOI:10.32604/biocell.2024.054510

    Abstract This article has no abstract. More >

  • Open Access

    ARTICLE

    Mitoxantrone and Etoposide for the Treatment of Acute Myeloid Leukemia Patients in First Relapse

    Annie Im, Ali Amjad, Mounzer Agha, Anastasios Raptis, Jing-Zhou Hou, Rafic Farah, Seah Lim, Alison Sehgal, Kathleen A. Dorritie, Robert L. Redner, Brian McLaughlin, Yongli Shuai, Shrina Duggal, Michael Boyiadzis

    Oncology Research, Vol.24, No.2, pp. 73-80, 2016, DOI:10.3727/096504016X14586627440156

    Abstract Relapsed acute myeloid leukemia (AML) represents a major therapeutic challenge. Achieving complete remission (CR) with salvage chemotherapy is the first goal of therapy for relapsed AML. However, there is no standard salvage chemotherapy. The current study evaluated outcomes and prognostic factors for achievement of CR in 91 AML patients in first relapse who were treated with the mitoxantrone–etoposide combination regimen. The overall response rate (CR and CRi) was 25%. Factors that were associated with a lower rate of CR included older age, shorter duration of first CR, low hemoglobin, and low platelet count. The median… More >

  • Open Access

    ARTICLE

    Circulating Tumor Cells Predict Prognosis Following Tyrosine Kinase Inhibitor Treatment in EGFR-Mutant Non-Small Cell Lung Cancer Patients

    Baohong Yang*1, Aiying Qin†1, Kongyuan Zhang, Haipeng Ren*, Shuzhen Liu*, Xiaolei Liu§, Xiangpo Pan, Guohua Yu*

    Oncology Research, Vol.25, No.9, pp. 1601-1606, 2017, DOI:10.3727/096504017X14928634401178

    Abstract Epithelial growth factor receptor (EGFR) mutations are present in 10%–26% of non-small cell lung cancer (NSCLC) tumors and are associated with the response to tyrosine kinase inhibitors (TKIs). This study aimed to detect and quantify the presence of circulating tumor cells (CTCs) in EGFR-mutant NSCLC patients and investigate their possible role in providing prognostic information. Enrolled patients received erlotinib (150 mg) or gefitinib (250 mg) orally once daily as the first-line treatment. Serial blood samples were taken at baseline (CTC-d0) and on day 28 (CTC-d28) following the initiation of erlotinib/gefitinib for detection of CTCs using… More >

  • Open Access

    ARTICLE

    CDGSH Iron Sulfur Domain 2 Activates Proliferation and EMT of Pancreatic Cancer Cells via Wnt/β-Catenin Pathway and Has Prognostic Value in Human Pancreatic Cancer

    Yang Yang, Yuan-song Bai, Qing Wang

    Oncology Research, Vol.25, No.4, pp. 605-615, 2017, DOI:10.3727/096504016X14767450526417

    Abstract Recently, increasing evidence has shown that CDGSH iron sulfur domain 2 (CISD2) is involved in the initiation and metastasis of several cancers. However, the evidence of its potential role in pancreatic cancer is still lacking. In our present study, CISD2 was found to be increased in pancreatic cancer samples and multiple cell lines. Moreover, statistical analysis revealed that a high level of CISD2 was related to advanced clinical stage, advanced T-stage, positive vascular invasion, positive distant metastasis, and larger tumor size. In addition, multivariate analysis suggests that CISD2 was an independent prognostic factor in pancreatic… More >

  • Open Access

    ARTICLE

    Prognostic Investigations of Expression Level of Two Genes FasL and Ki-67 as Independent Prognostic Markers of Human Retinoblastoma

    Samaneh Kouzegaran*, Kourosh Shahraki, Ali Makateb, Farkhondeh Shahri§, Negin Hatami, Vahid Behnod#, Amir Saber Tanha**

    Oncology Research, Vol.25, No.4, pp. 471-478, 2017, DOI:10.3727/096504016X14721217330657

    Abstract In this study, expression of FasL and Ki-67 messenger RNA (FasL and Ki-67 mRNA) in human retinoblastoma (HRB) was examined by the immunohistochemistry method and quantitative real-time PCR. Positive expression of Ki-67 in tumor cells was detected in 16 of 30 patients (53.33%), and only 9 (30%) of the tissues from patients with retinoblastoma showed positive staining for FasL. Our results revealed that FasL expression was significantly higher in tumor tissue with invasion compared with the noninvasion form (p = 0.033). Ki-67 expression was markedly increased in tumor tissues with invasion compared with the noninvasion group… More >

  • Open Access

    REVIEW

    MicroRNAs in thyroid cancer with focus on medullary thyroid carcinoma: potential therapeutic targets and diagnostic/prognostic markers and web based tools

    ELHAM SHAKIBA1, SETI BOROOMAND2, SIMA KHERADMAND KIA3, MEHDI HEDAYATI4,*

    Oncology Research, Vol.32, No.6, pp. 1011-1019, 2024, DOI:10.32604/or.2024.049235

    Abstract This review aimed to describe the inculpation of microRNAs (miRNAs) in thyroid cancer (TC) and its subtypes, mainly medullary thyroid carcinoma (MTC), and to outline web-based tools and databases for bioinformatics analysis of miRNAs in TC. Additionally, the capacity of miRNAs to serve as therapeutic targets and biomarkers in TC management will be discussed. This review is based on a literature search of relevant articles on the role of miRNAs in TC and its subtypes, mainly MTC. Additionally, web-based tools and databases for bioinformatics analysis of miRNAs in TC were identified and described. MiRNAs can… More > Graphic Abstract

    MicroRNAs in thyroid cancer with focus on medullary thyroid carcinoma: potential therapeutic targets and diagnostic/prognostic markers and web based tools

  • Open Access

    ARTICLE

    Identification prognostic features related to sphingolipid metabolism and experimental validation of TRIM47 in hepatocellular carcinoma

    JIAN TANG1, CHENQIANG ZHU1, YUN CHEN1, YUNLONG WU1, MING HE1, YI ZHOU2, MINGHUA XIE2,*

    BIOCELL, Vol.48, No.4, pp. 639-651, 2024, DOI:10.32604/biocell.2024.047562

    Abstract Background: The specific impact of sphingolipid metabolism on developing hepatocellular Carcinoma (HCC) remains unclear. This study aims to explore the relationship between sphingolipid metabolism and HCC prognosis, immune response, and drug sensitivity. Methods: Data were obtained from The Cancer Genome Atlas (TCGA)-Hepatocellular Carcinoma (LIHC) and Gene Expression Omnibus (GEO, GSE14520 datasets). 47 sphingolipid metabolism genes were obtained from the Kyoto Encyclopedia of Genes and Genomes (KEGG) database. After classifying HCC samples using the Non-negative Matrix Factorization (NMF) clustering method, differentially expressed genes were screened. Then, 8 risk genes were obtained by univariate analysis, survival random forest… More > Graphic Abstract

    Identification prognostic features related to sphingolipid metabolism and experimental validation of TRIM47 in hepatocellular carcinoma

  • Open Access

    ARTICLE

    IQGAP3 promotes the progression of glioma as an immune and prognostic marker

    XIAOFENG GAO1,2,3,4, JUANJUAN GE3, XUZHENG GAO1,3, NA MEI1,3, YANTING SU3, SHIGANG SHAN3, WENBIN QIAN3, JIANGHENG GUAN5, ZHENWANG ZHANG1,3,*, LONG WANG2,3,4,*

    Oncology Research, Vol.32, No.4, pp. 659-678, 2024, DOI:10.32604/or.2023.046712

    Abstract Background: IQGAP3 plays a crucial role in regulating cell proliferation, division, and cytoskeletal organization. Abnormal expression of IQGAP3 has been linked to various tumors, but its function in glioma is not well understood. Methods: Various methods, including genetic differential analysis, single-cell analysis, ROC curve analysis, Cox regression, Kaplan-Meier analysis, and enrichment analysis, were employed to analyze the expression patterns, diagnostic potential, prognostic implications, and biological processes involving IQGAP3 in normal and tumor tissues. The impact of IQGAP3 on immune infiltration and the immune microenvironment in gliomas was evaluated using immunofluorescence. Additionally, the cBioPortal database was used… More > Graphic Abstract

    IQGAP3 promotes the progression of glioma as an immune and prognostic marker

  • Open Access

    ARTICLE

    Development of a cell adhesion-based prognostic model for multiple myeloma: Insights into chemotherapy response and potential reversal of adhesion effects

    QIAN HU, MENGYAO WANG, JINJIN WANG, YALI TAO, TING NIU*

    Oncology Research, Vol.32, No.4, pp. 753-768, 2024, DOI:10.32604/or.2023.043647

    Abstract Multiple myeloma (MM) is a hematologic malignancy notorious for its high relapse rate and development of drug resistance, in which cell adhesion-mediated drug resistance plays a critical role. This study integrated four RNA sequencing datasets (CoMMpass, GSE136337, GSE9782, and GSE2658) and focused on analyzing 1706 adhesion-related genes. Rigorous univariate Cox regression analysis identified 18 key prognosis-related genes, including KIF14, TROAP, FLNA, MSN, LGALS1, PECAM1, and ALCAM, which demonstrated the strongest associations with poor overall survival (OS) in MM patients. To comprehensively evaluate the impact of cell adhesion on MM prognosis, an adhesion-related risk score (ARRS)… More >

  • Open Access

    ARTICLE

    GRIK1 promotes glioblastoma malignancy and is a novel prognostic factor of poor prognosis

    GUOQIANG HOU1,2,#, XINHANG XU2,#, WEIXING HU1,*

    Oncology Research, Vol.32, No.4, pp. 727-736, 2024, DOI:10.32604/or.2023.043391

    Abstract Primary tumors of the central nervous system (CNS) are classified into over 100 different histological types. The most common type of glioma is derived from astrocytes, and the most invasive glioblastoma (WHO IV) accounts for over 57% of these tumors. Glioblastoma (GBM) is the most common and fatal tumor of the CNS, with strong growth and invasion capabilities, which makes complete surgical resection almost impossible. Despite various treatment methods such as surgery, radiotherapy, and chemotherapy, glioma is still an incurable disease, and the median survival time of patients with GBM is shorter than 15 months.… More >

Displaying 1-10 on page 1 of 69. Per Page